Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2-PLLAV vaccine
- Development stage
- Preclinical
- Lead developer
- ViroVet
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The SARS-CoV-2-PLLAV vaccine is a preclinical vaccine candidate developed by ViroVet in collaboration with the Rega Institute at KU Leuven. It utilizes the proprietary Plasmid-Launched Live Attenuated Virus (PLLAV) technology platform. This approach involves the delivery of a DNA plasmid that, once inside host cells, initiates the production of a live attenuated version of the SARS-CoV-2 virus. This attenuated virus replicates locally to stimulate a broad and robust immune response, including both humoral and cellular immunity, mimicking a natural infection without causing disease. Preclinical studies in hamster models have demonstrated that the vaccine candidate can induce high levels of neutralizing antibodies and provide protection against viral challenge.
- Other names
- COVID-19 vaccine candidateCOVID19 vaccine candidateCOVID 19 vaccine candidateSARS-CoV-2 vaccine candidateSARS-CoV2 vaccine candidateSARS-CoV 2 vaccine candidateSARS-CoV-2-PLLAV vaccineSARS-CoV2-PLLAV vaccineSARS-CoV 2-PLLAV vaccine
Beyond the preview
Go deeper on SARS-CoV-2-PLLAV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2-PLLAV vaccine.